Navigation Links
Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
Date:11/19/2012

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease, as is employed in Cardium's Generx® gene therapy candidate currently in late-stage clinical studies. Following a decision by the European Patent Office, Cardium's patent portfolio now includes allowed and issued patents covering its gene therapy approach both in Europe and in the United States, with competing patent applications licensed and pursued by Boston Scientific having been successfully overcome in both Europe and the U.S.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The competing patent applications licensed by Boston Scientific Corporation had been filed by Dr. Jeffrey Leiden et al., currently President & CEO of Vertex Pharmaceuticals, and had been the subject of opposition proceedings in Europe and interference proceedings in the United States, both of which were ultimately resolved in favor of Cardium. Following resolution of the opposition proceedings and further examination of Cardium's case, the European Patent Office has now approved Cardium's patent application for grant in Europe. Three corresponding U.S. Patents that had been challenged by Boston Scientific Corporation (in decisions that were appealed to the United States Court of Appeals for the Federal Circuit), have been affirmed in Cardium's favor.

Cardium has additional patents and patent applications directed to its methods of cardio
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
2. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
3. Cardium to Present at Upcoming Investor Conferences
4. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 2012
5. MedCath Announces Extension of Tolling Agreement With U.S. Department of Justice
6. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results
7. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
8. Egenix, Inc. Announces New Director, John Reid
9. The Trendlines Group Announces Co-development Agreement with Endo
10. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
11. Sapio Sciences Announces Exemplar LIMS for Tablet Computers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... The Global and China Trifluoroacetic Acid Industry is ... of the Trifluoroacetic Acid industry in Global and China. ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... In a paper published this week in Science , ... and Professor Konstantin Novoselov has literally opened a third dimension ... prove the missing link for graphene to become the next ... is a remarkable material with endless unique properties, from ...
... 2012 InterMune, Inc. (NASDAQ: ITMN ) today ... year 2011 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 p.m. ... others may participate in the conference call by dialing 800-891-8257 ...
... Hudson, President and Scientific Director of The Ontario Institute ... to develop a framework for the implementation of personalized ... aims to integrate genomics research into everyday clinical practice, ... care for patients. Published in the journal ...
Cached Biology Technology:Graphene electronics moves into a third dimension 2InterMune to Release Fourth Quarter and Full Year Financial Results on February 9 2New Study Building Framework to Bring Personalized Medicine to the Clinic 2New Study Building Framework to Bring Personalized Medicine to the Clinic 3
(Date:8/28/2014)... available in German . ... built with the help of sophisticated assembly lines. Mobile assembly ... important part of these assembly lines. In the case of ... work stages arranged in a precise spatial and chronological sequence, ... line. , The creation of such an assembly line at ...
(Date:8/28/2014)... conserve biodiversity and more action is needed to ensure ... say. , Published in PLOS ONE , researchers ... Exeter, used meta-analysis - combining results from different studies ... research into these areas, to determine whether they actually ... Biological Sciences, said protecting an area from human exploitation ...
(Date:8/27/2014)... Aug. 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... sold in the offering consists of 2,000 shares of ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Protected areas proven to protect biodiversity 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... Illinois at Chicago College of Pharmacy are attempting ... antipsychotic medication works in adults and children and ... a popular "atypical" antipsychotic medication, is used to ... disorder. , Jeffrey Bishop, assistant professor of ...
... With wheat stem sawfly natural enemies in demand, ... increasing their availability. , This fall, the ... mass-rearing parasitic wasps that attack wheat stem sawfly ... plants. The team includes entomologists David Weaver, master's ...
... tool developed at Cambridge University represents a breakthrough in ... Huntington's disease. , Researchers have developed an effective ... the disease, using an automated touch screen. It is ... more effectively the cognitive difficulties in other neurodegenerative disorders ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Rearing an army to save wheat 2Rearing an army to save wheat 3New technology to speed up research into Huntington's disease 2New technology to speed up research into Huntington's disease 3
ATGL Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to SpUlp2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: SNNERQSLSSGSND, corresponding to amino acids 622-635 of Schizosaccharomyces pombe SpUlp2...
Lipid Phosphate Phosphohydrolase 2...
Request Info...
Biology Products: